Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia.
about
Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or realitySoluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice.Structural Basis for Ligand Recognition and Activation of RAGEMouse models to study the effect of cardiovascular risk factors on brain structure and cognitionImmunohistochemical study of N-epsilon-carboxymethyl lysine (CML) in human brain: relation to vascular dementia.Plasma levels of the pro-inflammatory protein S100A12 (EN-RAGE) are associated with muscle and fat mass in hemodialysis patients: a cross-sectional study.Receptor for advanced glycation end products is upregulated in optic neuropathy of Alzheimer's disease.Association of the RAGE G82S polymorphism with Alzheimer's disease.Food intake and blood cholesterol levels of community-based adults with mood disorders.Plasma levels of sRAGE, loss of aeration and weaning failure in ICU patients: a prospective observational multicenter studyAssociation of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS)Plasma levels of soluble receptor for advanced glycation end products in patients with acute respiratory distress syndromeSerum level of endogenous secretory receptor for advanced glycation end products and other factors in type 2 diabetic patients with mild cognitive impairmentThe association of diabetes and dementia and possible implications for nondiabetic populations.Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products.Soluble RAGEs - Prospects for treating & tracking metabolic and inflammatory diseaseEmerging Targets for Therapeutic Development in Diabetes and Its Complications: The RAGE Signaling Pathway.Effects of Fructus mume Extract on MAPK and NF-κB Signaling and the Resultant Improvement in the Cognitive Deficits Induced by Chronic Cerebral Hypoperfusion.RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer's disease.RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases.Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease.Diabetic threesome (hyperglycaemia, renal function and nutrition) and advanced glycation end products: evidence for the multiple-hit agent?Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene.Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases.Nodes and biological processes identified on the basis of network analysis in the brain of the senescence accelerated mice as an Alzheimer's disease animal model.Levels of Soluble Receptor for Advanced Glycation End Products in Acute Ischemic Stroke without a Source of Cardioembolism.Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury.Complex tissue-specific patterns and distribution of multiple RAGE splice variants in different mammals.Crosstalk between calcium, amyloid beta and the receptor for advanced glycation endproducts in Alzheimer's disease.Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis.What is the role of the receptor for advanced glycation end products-ligand axis in liver injury?Neuronal receptors as targets for the action of amyloid-beta protein (Aβ) in the brain.Reasons to Investigate the Soluble Receptor for Advanced Glycation End-Product (sRAGE) Pathway in Aortic Disease.Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective.Cerebrospinal fluid biomarkers and HIV-associated neurocognitive disorders in HIV-infected individuals in Rakai, Uganda.RAGE-TLR Crosstalk Sustains Chronic Inflammation in Neurodegeneration.AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease.Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis.The S100B/RAGE Axis in Alzheimer's Disease.Endogenous Secretory RAGE as a Novel Biomarker for Metabolic Syndrome and Cardiovascular Diseases.
P2860
Q26859793-A26654D0-5AFD-472A-8A34-7A46E45D4255Q27319831-5040B567-EE29-492B-B1D4-CF716E181CD5Q27665039-73297361-0065-44BD-88F7-F5CBB503744BQ30427103-B9D76E09-C9DE-4CF5-B234-1FEB7F7ACB17Q33302856-94FC28CE-ACED-4CC4-8928-C07488C9133EQ33723012-B47DED9E-4D3D-41A7-AD8D-B94FF399233BQ33841564-B061FC0F-08F2-42F1-A00B-83E1C6D612FCQ33956505-78A3FCDD-EB39-45B2-89E7-B8EC0575C9FEQ34158786-F4646057-0729-4442-B6DE-EEE2DE79D07BQ34749439-6321809D-4292-45D5-A669-C8D11F9814CDQ34949171-249A63CA-EC5A-4002-98D7-040D76169355Q35017280-5A0A6F6B-2B5D-4AEC-B8CB-CD03D64D7B38Q35563671-5EC26EF5-FBE1-415E-9451-18C28DA46F9CQ35619553-5FAD4E44-9818-491A-A93F-569B6D86A58DQ35882416-3B627D93-9748-4286-B0B9-669FE71DE9C1Q35991574-22E45EA2-DE36-4912-8928-E8DED5FABEDDQ36207823-5FCFDF2E-7907-442B-A971-EB501BDCB50FQ36537983-083E50F9-46C2-4590-BFC4-C3701D62AB61Q36942363-E53F2823-1290-4A86-8A74-8760F47D6B65Q36969021-90003561-B331-4600-8BE7-998BB5649537Q37068847-6FE85678-9A27-48B9-9E6C-1A31F16959DFQ37072018-D518E80D-2328-4F52-92D3-B07331823496Q37233185-0C4499F8-D47B-4E65-9BD7-4DDF15FDF4BDQ37259863-19E5D4F6-9655-46B8-B337-0F5D90FCCC6EQ37261529-50A047BF-34A3-414A-8A9C-B90AB2EF2A5EQ37384595-E0E30830-3B8C-4E57-B301-9D8526FCB1E9Q37393702-80B1C78C-D4C1-414B-859C-8AAF7A56EA21Q37430071-4F0A5E17-8A20-4BEE-9189-9657F024C703Q37602130-FBAFAD3B-EAB0-4D94-BA16-98B82A7B5B5AQ37857377-E78BACA1-0502-4882-B858-3D152B49682DQ37857797-E0675275-8534-48A4-B3F6-63DE1BB4DE4CQ37977251-763E0614-5373-4643-A23C-D56A54E8BAF1Q38370045-49DDC9BF-94D1-4943-B61C-3EE2DC3C35D0Q38686477-E6978F5B-4710-45E5-BD88-72C6AC44B597Q38851823-0346AC5B-857B-49CD-9878-488C1FB673EFQ39123617-3BA65A01-3CEA-4ED2-A5C5-8F09A5E3FB40Q39313922-059729E1-2CE1-4262-A4F0-3720EF70EB74Q41871282-E7805E18-66C3-4E57-9792-E8E557333EEAQ42151789-537BA953-64BB-4120-92A6-1D1283585216Q42176457-E0397CF9-E5F8-459A-82D5-538B1691F5E6
P2860
Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia.
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Circulating levels of soluble ...... disease and vascular dementia.
@ast
Circulating levels of soluble ...... disease and vascular dementia.
@en
Circulating levels of soluble ...... disease and vascular dementia.
@nl
type
label
Circulating levels of soluble ...... disease and vascular dementia.
@ast
Circulating levels of soluble ...... disease and vascular dementia.
@en
Circulating levels of soluble ...... disease and vascular dementia.
@nl
prefLabel
Circulating levels of soluble ...... disease and vascular dementia.
@ast
Circulating levels of soluble ...... disease and vascular dementia.
@en
Circulating levels of soluble ...... disease and vascular dementia.
@nl
P2093
P50
P1433
P1476
Circulating levels of soluble ...... disease and vascular dementia
@en
P2093
Amalia C Bruni
Angela D'Angelo
Carmine Tomaino
Diego Geroldi
Livia Bernardi
Raffaele Maletta
P304
P356
10.1001/ARCHNEUR.62.11.1734
P577
2005-11-01T00:00:00Z